Caroline Hopkins

A new analysis from the Phase II APPLE trial showed minimal differences in overall survival, though the newer generation TKI significantly reduced brain metastases.

The firm will submit data from the GLOW and SPOTLIGHT studies to regulators and seek approval for zolbetuximab plus chemo in CLDN18.2-positive HER2-negative advanced gastric cancer.

Researchers in Australia, Germany, and the US are in the early stages of developing a prostate cancer radiopharmaceutical they say could be manufactured in-house via a desktop machine.

At a recent Friends of Cancer Research meeting, drugmakers and regulators said communication has improved on cell therapy development programs but acknowledged persistent challenges.

Novartis has admitted it underestimated demand for the radiopharmaceutical, though the FDA's approval of a US-based manufacturing facility may provide some relief by summer.

The makers of several PARP inhibitors shared data they said support using these drugs with anti-androgen therapy in all advanced prostate cancer patients, but oncologists want more biomarker data.

The firm is evaluating if an oral pill containing the bacteria Akkermansia can improve immunotherapy responses among lung and kidney cancer patients.

The drugmaker is expecting Trodelvy sales to increase even more this year if the FDA approves a broader breast cancer indication later this month.

During an earnings call, the company's executives detailed strategies for replacing revenue from its bestselling drug Keytruda, slated to lose market exclusivity in coming years.

The Swiss drugmaker's CDK4/6 inhibitor Kisqali saw significant sales growth, as did newly launched therapies Pluvicto and Scemblix.